Previous studies have indeed suggested that SEC61G can serve as an effective marker for predicting worse prognosis in several cancer types, including lung cancer, breast cancer, kidney cancer, head and neck cancer, and hepatocellular carcinoma (HCC). This evidence concerns the gene SEC61G and kidney cancer.